Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS), a clinical-stage metabolic therapeutics company focused on obesity and type 2 diabetes, announced it will report its second quarter 2026 financial results and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
According to Fractyl Health, investors and the public can access a live webcast of the conference call and presentation in the “Events” section of its investor relations website at http://ir.fractyl.com. The webcast will be archived for replay after the live event.
Positive
- None.
Negative
- None.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Earnings date | Neutral | -0.2% | Prior announcement scheduled fourth-quarter and full-year 2025 results for March 24, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The comparable prior earnings-date announcement was followed by a -0.2% 24-hour move; the pre-headline GUTS change was -0.72%.
Key Terms
t2d medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies. Fractyl’s goal is to advance metabolic disease treatment from chronic management toward prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200